1. Opening Hook
Just when pharma stocks were deciding whether to rally or nap, Innova Captab walked in with a 42% YoY revenue jump and a straight face.
The MD sounded calm, analysts sounded curious, and margins… well, they politely stayed where they were.
Q3 FY26 was less about fireworks and more about disciplined execution—CDMO orders ticking up, branded generics going full gym mode, and the Jammu plant still warming up its engines. Certifications from UK-MHRA and PIC/S arrived like external validation stickers.
At first glance, this looks like a clean growth story. Dig deeper, and you’ll notice PAT growing slower than revenue, working capital getting heavier, and depreciation quietly flexing.
Read on—because the real story isn’t growth. It’s how sustainable that growth really is.
2. At a Glance
- Revenue up 42% – Management says “execution”; markets say “finally!”
- EBITDA up 40% – Growth showed up, margins didn’t overreact.
- PAT up 23% – Profits jogged while revenue sprinted.
- Branded Generics up 79% – Domestic + exports clearly had caffeine.
- CDMO up 29% – Slow, steady, and predictable—like investors like it.
- Exports at 35% mix – Global dreams, with regulatory homework done.
3. Management’s Key Commentary
“We delivered accelerated YoY revenue growth of 42% in Q3 FY26.”
(Translation: Please notice the headline number first.) 😏
“Growth was driven by improved client engagement in CDMO and geographic expansion.”
(Translation: Same clients, more orders; same geographies, more SKUs.)
“We
